More than 2.3 million people globally are infected with both HIV and hepatitis C (HCV) viruses, finds a new study.
Of these, more than half, or 1.3 million, are people who inject drugs (PWID) -- HIV infections caused by injecting drugs.
The study revealed that HIV-infected people are on an average six times more likely than HIV-uninfected people to have HCV infection.
"The study shows that not only are people with HIV at much higher risk of HCV infection, groups such as people who inject drugs have extremely high prevalence of HCV infection - over 80 percent," said Philippa Easterbrook, from WHO's Global Hepatitis Programme.
HIV and HCV infections are major global public health problems, with overlapping modes of transmission and affected populations.
Globally, there are 37 million people infected with HIV and around 115 million people with chronic HCV infection.
"Improvement in the surveillance of HCV and HIV is imperative to help define the epidemiology of coinfection and inform appropriate policies for testing, prevention, care and treatment to those in need," said lead author Lucy Platt, senior lecturer at University of London.
The study shows the need to scale up prevention interventions, such as needle and syringe programmes and opioid substitution therapy, as well as access to HIV and HCV treatment, to reduce morbidity and new infections, the researchers suggested.
The study, published online in The Lancet Infectious Diseases, systematically reviewed 783 medical studies from worldwide sources to build the first global estimates on the prevalence of HIV/HCV co-infection (measured by HCV antibody) as a public health problem.
The researchers included studies with estimates of HCV co-infection in the main HIV population, as well as sub-groups of PWID, homosexuals, pregnant women and the general population.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)